Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Treatments

Topic: Risk, prevention and care in population studies

Plain-language summary

Background Impairment of multiple neurotransmitter networks, including acetylcholine, may contribute to the cognitive impairment in patients with Parkinson disease with dementia (PDD). Therefore, cholinesterase inhibitors might improve cognitive function in PDD. On the other hand, enhancing cholinergic function could plausibly worsen features of parkinsonism. Objective To determine if oral cholinesterase inhibitors improve measures of cognitive outcome and are tolerated by people with PDD. Methods We addressed the question through the development of a critically appraised topic. Participants included consultant and resident neurologists, clinical epidemiologists, a medical librarian, and behavioral neurology and movement disorder specialists. Participants began with a structured clinical question, devised search strategies, compiled the best evidence, performed a critical appraisal, summarized the evidence, provided commentary, and declared bottom-line conclusions. Results A randomized controlled trial (n = 541) showed that, compared with placebo, rivastigmine (mean, 8.6 mg/d) significantly improved scores on 2 coprimary cognitive outcome scales in PDD, including the Alzheimer disease Cooperative Study-Clinician's Global Impression of Change. When dichotomized to evaluate clinically significant benefit (moderate or marked improvement), this outcome was not significant (risk difference = 5.3%; 95% confidence interval (CI) = -1.6 to 12.1). The number needed to treat (NNT) to avoid clinically significant worsening of cognition was 10 (95% CI = 6-28). The NNT for the combined outcome of either achieving clinically significant benefit or avoiding significant worsening was 7. The numbers needed to harm for cholinergic side effects were 9 (95% CI = 5-24) for parkinsonian symptoms and 11 (95% CI = 6-32) for rivastigmine discontinuation due to any side effect. Conclusion Rivastigmine therapy for PDD is associated with significant tradeoffs in efficacy and adverse effects. Carefully monitored trials of rivastigmine may provide meaningful benefits for a minority of PDD patients.

What this study adds

Evidence grade: High

This is a trial of 541 participants. This review of a 541-person randomized trial found that rivastigmine improved scores on two cognitive scales in people with Parkinson disease dementia, but the difference was not significant when judged by clinically meaningful benefit. Reported effect size: 5.3%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Almaraz, A. C., Driver-Dunckley, E. D., Woodruff, B. K., Wellik, K. E., Caselli, R. J., Demaerschalk, B. M., et al. (2009). Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia. The neurologist. https://doi.org/10.1097/nrl.0b013e3181a968df

Vancouver

Almaraz AC, Driver-Dunckley ED, Woodruff BK, Wellik KE, Caselli RJ, Demaerschalk BM, et al. Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia. The neurologist. 2009. doi:10.1097/nrl.0b013e3181a968df. PMID: 19590387.

BibTeX

@article{almaraz2009-19590387,
  author  = {Almaraz, A. C. and Driver-Dunckley, E. D. and Woodruff, B. K. and Wellik, K. E. and Caselli, R. J. and Demaerschalk, B. M. and Adler, C. H. and Caviness, J. N. and others},
  title   = {{Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia}},
  journal = {The neurologist},
  year    = {2009},
  doi     = {10.1097/nrl.0b013e3181a968df},
  pmid    = {19590387},
  url     = {https://doi.org/10.1097/nrl.0b013e3181a968df}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This review of a 541-person randomized trial found that rivastigmine improved scores on two cognitive scales in people with Parkinson disease dementia, but the difference was not significant when judged by clinically meaningful benefit. The authors also note that boosting cholinergic function could plausibly worsen parkinsonism.

Study details

How this study scored 55/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 12 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 2 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 3 of 7; Citations per year 0 of 5; Impact for its field and year 1 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 55 of 100.55 of 100 points earned45 not earned

Published in a peer-reviewed journal, and it is a meta-analysis pooling many studies.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (The neurologist)
Journal's citation record 1 / 4 The Neurologist: journal h-index 78 (OpenAlex, 2026-10-29)
Study design 12 / 12 A meta-analysis pooling many studies (from PubMed type “Meta-Analysis”)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2009 — within 20 year(s) of the newest study here
Sample size 2 / 4 541 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 A review of other studies — randomization is not credited here
Times cited 3 / 7 Cited 15 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.8 citations a year over 19 year(s) since 2009
Impact for its field and year 1 / 6 Cited 0.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Dean M. Wingerchuk: h-index 71 (OpenAlex, whole career)
Institution's track record 2 / 3 Mayo Clinic: institution h-index 1,606 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 19590387)
Free to read 0 / 2 Behind a paywall — scores zero
Total 55 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Treatments from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →